David Buck
Stock Analyst at B. Riley Securities
(0.24)
# 4,168
Out of 4,862 analysts
14
Total ratings
21.43%
Success rate
-27.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Buck
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNOV MediciNova | Assumes: Buy | $22 | $1.33 | +1,554.14% | 2 | Mar 25, 2019 | |
| SUPN Supernus Pharmaceuticals | Maintains: Buy | $68 → $65 | $32.03 | +102.93% | 3 | Nov 12, 2018 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $219 → $190 | $108.50 | +75.12% | 4 | Nov 8, 2018 | |
| AMRX Amneal Pharmaceuticals | Maintains: Buy | $26 → $28 | $7.76 | +261.06% | 2 | Aug 22, 2018 | |
| ALKS Alkermes | Initiates: Buy | $60 | $29.82 | +101.21% | 1 | Jun 6, 2018 | |
| EVOK Evoke Pharma | Reinstates: Buy | $1,440 | $2.81 | +51,145.55% | 2 | Oct 19, 2017 |
MediciNova
Mar 25, 2019
Assumes: Buy
Price Target: $22
Current: $1.33
Upside: +1,554.14%
Supernus Pharmaceuticals
Nov 12, 2018
Maintains: Buy
Price Target: $68 → $65
Current: $32.03
Upside: +102.93%
Jazz Pharmaceuticals
Nov 8, 2018
Maintains: Buy
Price Target: $219 → $190
Current: $108.50
Upside: +75.12%
Amneal Pharmaceuticals
Aug 22, 2018
Maintains: Buy
Price Target: $26 → $28
Current: $7.76
Upside: +261.06%
Alkermes
Jun 6, 2018
Initiates: Buy
Price Target: $60
Current: $29.82
Upside: +101.21%
Evoke Pharma
Oct 19, 2017
Reinstates: Buy
Price Target: $1,440
Current: $2.81
Upside: +51,145.55%